Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Stefania Proietti, Florindo d’Onofrio et al.|Journal of Neurology|2024Cited by 37
Responders and super-responders to atogepant after 24 weeks of treatment in migraine: real-world evidence from the GIANT-2 studyPiero Barbanti, Alfonso Coppola, Gabriella Egeo et al.|The Journal of Headache and Pain|2026Cited by 0